These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26719706)

  • 1. The role of CD44 in epithelial-mesenchymal transition and cancer development.
    Xu H; Tian Y; Yuan X; Wu H; Liu Q; Pestell RG; Wu K
    Onco Targets Ther; 2015; 8():3783-92. PubMed ID: 26719706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 as a tumor biomarker and therapeutic target.
    Xu H; Niu M; Yuan X; Wu K; Liu A
    Exp Hematol Oncol; 2020 Dec; 9(1):36. PubMed ID: 33303029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
    Geng S; Guo Y; Wang Q; Li L; Wang J
    Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer.
    Ryu HS; Park DJ; Kim HH; Kim WH; Lee HS
    Hum Pathol; 2012 Apr; 43(4):520-8. PubMed ID: 22018628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
    Oon ML; Thike AA; Tan SY; Tan PH
    Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
    Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
    J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology and role of CD44 in cancer progression: therapeutic implications.
    Chen C; Zhao S; Karnad A; Freeman JW
    J Hematol Oncol; 2018 May; 11(1):64. PubMed ID: 29747682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic Value of CD44 Expression in Epithelial-Mesenchymal Transition: Preliminary Data from Patients with Gastric and Esophageal Cancer.
    Schizas D; Moris D; Kanavidis P; Michalinos A; Sioulas A; Pavlakis K; Machairas A; Liakakos T
    In Vivo; 2016 11-12; 30(6):939-944. PubMed ID: 27815484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.
    Guo JY; Hsu HS; Tyan SW; Li FY; Shew JY; Lee WH; Chen JY
    Oncogene; 2017 Apr; 36(17):2457-2471. PubMed ID: 27819672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
    Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
    Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition.
    Gao Y; Ruan B; Liu W; Wang J; Yang X; Zhang Z; Li X; Duan J; Zhang F; Ding R; Tao K; Dou K
    Oncotarget; 2015 Apr; 6(10):7828-37. PubMed ID: 25797261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion.
    Cho SH; Park YS; Kim HJ; Kim CH; Lim SW; Huh JW; Lee JH; Kim HR
    Int J Oncol; 2012 Jul; 41(1):211-8. PubMed ID: 22552741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for circulating cancer stem-like cells and epithelial-mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy.
    Mirza S; Jain N; Rawal R
    Tumour Biol; 2017 Mar; 39(3):1010428317695915. PubMed ID: 28347243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1.
    Zhou J; Du Y; Lu Y; Luan B; Xu C; Yu Y; Zhao H
    Front Oncol; 2019; 9():802. PubMed ID: 31497537
    [No Abstract]   [Full Text] [Related]  

  • 15. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
    Sosulski A; Horn H; Zhang L; Coletti C; Vathipadiekal V; Castro CM; Birrer MJ; Nagano O; Saya H; Lage K; Donahoe PK; Pépin D
    PLoS One; 2016; 11(6):e0156595. PubMed ID: 27253518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.
    Wu CT; Lin WY; Chen WC; Chen MF
    Ann Surg Oncol; 2018 Nov; 25(12):3518-3526. PubMed ID: 30128900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
    Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
    J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells.
    Senbanjo LT; Chellaiah MA
    Front Cell Dev Biol; 2017; 5():18. PubMed ID: 28326306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
    Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
    Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
    Mikami S; Mizuno R; Kosaka T; Saya H; Oya M; Okada Y
    Int J Cancer; 2015 Apr; 136(7):1504-14. PubMed ID: 25123505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.